European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
GlobeNewswire, Inc.
RASONQUE once-daily oral tablets indicated as a monotherapy for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy Approval includes patients with or without an...
Zealand Pharma announces EU approval of Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
GlobeNewswire, Inc.
Press release – No. 24 / 2026 Zealand Pharma announces EU approval of ZeydovioTM (glepaglutide) for the treatment of short bowel syndrome The approval marks the first major advancement in short bowel syndrome treatment in Europe in more than a...
CDC Report Reveals Shortfall in Omega-3s Essential to Heart and Brain Health, Underscoring Value of Test-Based Nutrition
EIN Presswire
With 98% of Americans falling short on EPA and DHA, Zinzino’s Test-Based Nutrition offers a simple, measurable way to track omega-3 levels.
SERB Pharmaceuticals Announces Positive Results from the Post-Authorisation Efficacy Study of Idefirix® (imlifidase) Presented at ASN Kidney Week 2026
GlobeNewswire, Inc.
Study met its primary objective: 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful Graft and patient survival were 92% and 98%, respectively Idefirix® was generally well tolerated with a safety...
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
GlobeNewswire, Inc.
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: Licaminlimab is positioned...
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
GlobeNewswire, Inc.
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for patients with retinal...
Milestone for Icelandic tourism industry
Chaponda courts Norwegian, Icelandic investment
Video Stories
Sign up for:
Iceland Health Focus
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.